Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease
NCT ID: NCT02227355
Last Updated: 2016-07-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
195 participants
OBSERVATIONAL
2014-09-30
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease
NCT02230904
Transdermal Rotigotine User Surveillance Study
NCT00599339
Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
NCT01338896
Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
NCT00143026
Subthalamic Steering for Therapy Optimization in Parkinson's Disease
NCT03548506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PD Patients < 70 years of age
Patients with Parkinson's Disease (PD) \<70 years of age.
No interventions assigned to this group
PD Patients ≥ 70 years of age
Patients with Parkinson's Disease (PD) ≥ 70 years of age.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The decision by the treating physician to prescribe Rotigotine transdermal patch is made before participating in the NIS due to a clinical therapeutic indication (e.g., because of intolerance and/or ineffectiveness of another dopamine agonist)
* The patient is either male or female and over 18 years of age
* A Patient Data Consent form is signed and dated by the patient or by the legal representative
* The patient has idiopathic Parkinson's Disease, has not received Rotigotine within 28 days prior to the Baseline Visit and is willing to participate in questionnaire based assessments
* The patient is receiving L-dopa as monotherapy or a combination therapy composed of L-dopa and a dopamine agonist other than Rotigotine
* The patient has been on L-dopa therapy for at least 6 months and is responding to initial L-dopa therapy
* The patient has a Hoehn and Yahr stage score of 1 to 4.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PRA Health Sciences
INDUSTRY
UCB Biopharma S.P.R.L.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
42
Lille, , France
41
Mougins, , France
40
Nîmes, , France
6
Alzenau in Unterfranken, , Germany
51
Aschaffenburg, , Germany
13
Beelitz-Heilstätten, , Germany
12
Berlin, , Germany
5
Böblingen, , Germany
53
Düsseldorf, , Germany
7
Erbach im Odenwald, , Germany
4
Haag, , Germany
11
Leer, , Germany
2
Münster, , Germany
54
Schriesheim, , Germany
8
Senftenberg, , Germany
14
Tübingen, , Germany
10
Ulm, , Germany
3
Westerstede, , Germany
45
Ancona, , Italy
47
Brescia, , Italy
60
Cagliari, , Italy
29
Cosenza, , Italy
30
Florence, , Italy
46
Milan, , Italy
27
Napoli, , Italy
28
Roma, , Italy
62
Roma, , Italy
20
Barakaldo, , Spain
15
Donostia / San Sebastian, , Spain
24
Madrid, , Spain
22
Palma de Mallorca, , Spain
37
Bury, , United Kingdom
49
Cambridge, , United Kingdom
52
Lincoln, , United Kingdom
48
Liverpool, , United Kingdom
33
London, , United Kingdom
36
London, , United Kingdom
34
Manchester, , United Kingdom
31
Middlesbrough, , United Kingdom
38
North Shields, , United Kingdom
35
Norwich, , United Kingdom
63
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PD0013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.